Your Article Summary
Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas
PLoS ONE - Cardiovascular Disorders, 09/14/09
Dorsey ER et al. – Across therapeutic areas, biomedical research funding increased substantially, appears aligned with disease burden in high income countries, but is not linked to new drug approvals. The translational gap between funding and new therapies is affecting all of medicine, and remedies must include changes beyond additional financial investment.
Related Articles
Problems of Quality and Equity in Pain Management: Exploring the Role of Biomedical Culture
Pain Medicine, 10/14/09
Relevance Score: 67%
Reinvesting in US Biomedical Research-The Time is Now
Gastroenterology, 10/05/09
Relevance Score: 67%
President Obama Announces Recovery Act Grants for Medical Research
AAMC Newsroom, 10/02/09
Relevance Score: 67%
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09
Relevance Score: 65%
Expectant moms, babies subjects of new Singapore study to prevent obesity and diabetes in adults
EurekAlert, 11/10/09
Relevance Score: 65%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09
Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Diabetes experts underline benefits of SMBG for all types of treatment plans
BayNews International, 11/30/09
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Article Search
Sponsor


See Latest Articles


